High‐dose PPI‐amoxicillin dual therapy with or without bismuth for first‐line Helicobacter pylori therapy: A randomized trial
出版年份 2019 全文链接
标题
High‐dose PPI‐amoxicillin dual therapy with or without bismuth for first‐line
Helicobacter pylori
therapy: A randomized trial
作者
关键词
-
出版物
HELICOBACTER
Volume -, Issue -, Pages e12596
出版商
Wiley
发表日期
2019-05-21
DOI
10.1111/hel.12596
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Interchangeable Use of Proton Pump Inhibitors Based on Relative Potency
- (2018) David Y. Graham et al. Clinical Gastroenterology and Hepatology
- Tu1299 - Vonoprazan-Based Dual Therapy with Amoxicillin is as Effectve as the Triple Therapy for the Eradication of H. Pylori
- (2018) Takahisa Furuta et al. GASTROENTEROLOGY
- Update on the Use of Vonoprazan: A Competitive Acid Blocker
- (2018) David Y. Graham et al. GASTROENTEROLOGY
- Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies
- (2018) David Y. Graham et al. Expert Review of Anti-Infective Therapy
- Relative potency of proton-pump inhibitors, Helicobacter pylori therapy cure rates, and meaning of double-dose PPI
- (2018) David Y. Graham et al. HELICOBACTER
- Optimized high-dose amoxicillin–proton-pump inhibitor dual therapies fail to achieve high cure rates in China
- (2017) Dian-Chun Fang et al. Saudi Journal of Gastroenterology
- Failure of optimized dual proton pump inhibitor amoxicillin therapy: What now?
- (2017) DavidY Graham et al. Saudi Journal of Gastroenterology
- Management ofHelicobacter pyloriinfection—the Maastricht V/Florence Consensus Report
- (2016) P Malfertheiner et al. GUT
- Role of bismuth in improvingHelicobacter pylorieradication with triple therapy
- (2016) Maria Pina Dore et al. GUT
- High Dose Ilaprazole/Amoxicillin as First-Line Regimen forHelicobacter pyloriInfection in Korea
- (2016) WonGun Kwack et al. Gastroenterology Research and Practice
- Colloidal bismuth subcitrate impedes proton entry intoHelicobacter pyloriand increases the efficacy of growth-dependent antibiotics
- (2015) E. A. Marcus et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole
- (2014) S. Sahara et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- High-Dose Extended-Release Lansoprazole (Dexlansoprazole) and Amoxicillin Dual Therapy forHelicobacter pyloriInfections
- (2014) Taraq A. Attumi et al. HELICOBACTER
- New dual therapy for primary treatment ofHelicobacter pyloriinfection: A prospective randomized study in Shanghai, China
- (2014) Ling Ren et al. Journal of Digestive Diseases
- Effect of dosing schemes of amoxicillin on eradication rates ofHelicobacter pyloriwith amoxicillin-based triple therapy
- (2013) Takahisa Furuta et al. JOURNAL OF CLINICAL PHARMACOLOGY
- The effects of varying acidity onHelicobacter pylorigrowth and the bactericidal efficacy of ampicillin
- (2012) E. A. Marcus et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection
- (2012) A. G. McNicholl et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Dual proton pump inhibitor plus amoxicillin as an empiric anti-H. pylori therapy: studies from the United States
- (2010) David Y. Graham et al. JOURNAL OF GASTROENTEROLOGY
- New concepts of resistance in the treatment of Helicobacter pylori infections
- (2008) David Y Graham et al. Nature clinical practice. Gastroenterology & hepatology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More